Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jacob J. Adashek"'
Autor:
Mahati Paravathaneni, Houssein Safa, Vidhu Joshi, Monica K. Tamil, Jacob J. Adashek, Filip Ionescu, Savan Shah, Juskaran S. Chadha, Scott Gilbert, Brandon Manley, Adele Semaan, Heather S.L. Jim, Denise Kalos, Youngchul Kim, Philippe E. Spiess, Jad Chahoud
Publikováno v:
EClinicalMedicine, Vol 68, Iss , Pp 102413- (2024)
Summary: Background: Standardized, high-quality PRO data reporting is crucial for patient centered care in the field of oncology, especially in clinical trials that establish standard of care. This study evaluated PRO endpoint design, conduct and rep
Externí odkaz:
https://doaj.org/article/f8367ce4344b45879a82f1322cc3d99e
Publikováno v:
Cells, Vol 8, Iss 8, p 860 (2019)
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signa
Externí odkaz:
https://doaj.org/article/ccff4f1d88074dd2ae8d6bcc44180240
Autor:
Edwin M. Posadas, Ankita Tandon, Robert A. Figlin, Stephen J. Freedland, Jacob J. Adashek, Jarred P. Reed, Jun Gong, Leland W.K. Chung, Neil A. Bhowmick, Michael R. Freeman
Publikováno v:
Clin Genitourin Cancer
The addition of docetaxel and abiraterone to androgen deprivation therapy (ADT) heralded a new era in the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Following the success of these combination regimens, 3 new tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b992fc05bd331a57940d2c3fd75bf1
https://europepmc.org/articles/PMC9212901/
https://europepmc.org/articles/PMC9212901/
Autor:
Vivek Subbiah, Jacob J. Adashek, Arjun K. Menta, Alex Leonard, Pavlos Msaouel, Jason Roszik, Giannicola Genovese
Publikováno v:
Cancers, Vol 12, Iss 3, p 710 (2020)
Cancers
Cancers
This article aims to summarize the current literature on genetic alterations related to tumors of the genitourinary tract. Novel associations have recently been reported between specific DNA alterations and genitourinary malignancies. The most common
Publikováno v:
Urology Case Reports
Although the outcomes have improved in metastatic castrate-resistant prostate cancer (mCRPC), there is a limited arsenal of treatment options at the oncologist's disposal. The options range from enzalutamide and abiraterone (hormone-based therapies),
Autor:
Paulo Gustavo Bergerot, Meghan Salgia, Sumanta K. Pal, Kemi Ashing-Giwa, Brendan N. Cotta, Nazli Dizman, Jacob J. Adashek, Mina S. Sedrak, Andrew R. Wong, Cristiane Decat Bergerot
PURPOSE Several studies have described the content of Twitter conversations about lung, breast, and prostate cancer, but little is known about how the public uses Twitter to discuss kidney cancer. We sought to characterize the content of conversation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e195c100e94055e83235bd2b8793bfc
https://europepmc.org/articles/PMC6874008/
https://europepmc.org/articles/PMC6874008/
Autor:
Saihitha Veerapaneni, Neeraj Agarwal, Roberto Nussenzveig, Christopher Szeto, Sumanta K. Pal, Elias Obeid, Sandeep K. Reddy, Jacob J. Adashek
Publikováno v:
Molecular Cancer Therapeutics. 18:B093-B093
Background: BC and CRC are heterogeneous diseases with several distinct disease subtypes. A 50-gene qPCR assay (PAM50) identifies 5 intrinsic biological subtypes: luminal A, luminal B, HER2-enriched, basal-like, and normal-like in breast cancer. Cons
Autor:
Przemyslaw Twardowski, Sumanta K. Pal, Marcin Kortylewski, Jacob J. Adashek, Priyanka Duttagupta, Jeremy O. Jones, Dayson Moreira, Haejung Won
Publikováno v:
Journal of Clinical Oncology. 37:296-296
296 Background: IL-6 is an upstream regulator of various moieties, including STAT3, that are associated with a poor prognosis in mCRPC. The specific association between these moieties and outcomes with enza and abi are as yet undefined. Methods: Pts